Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

Author(s):

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

The phase 2 GRIFFIN study evaluated the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) versus the standard triplet regimen of RVd in patients with transplant-eligible, newly diagnosed multiple myeloma.

Updated results of the study, which were presented during the 2020 ASH Annual Meeting & Exposition, demonstrated a 42.4% stringent complete response (sCR) rate with D-RVd versus 32.0% with RVd at a median follow-up of 13.5 months. Notably, with additional daratumumab/lenalidomide or lenalidomide maintenance therapy, responses deepened and remained higher for the D-RVd group versus the RVd group. At a median follow-up of 26.7 months, the sCR rate continued to favor D-RVd versus RVd (63.6% and47.4%, respectively), Voorhees adds.

Furthermore, minimal residual disease (MRD)–negativity (defined as 10‑5 threshold per International Myeloma Working Group criteria) rates favored D-RVd versus RVd (62.5% and 27.2%, respectively) in the intention-to-treat (ITT) population, as well as among patients who achieved a CR or better (76.5% and 42.4%, respectively). MRD negativity (defined as 10‒6) rates also favored D-RVd versus RVd in the ITT population (26.9% and 12.6%, respectively), as well as among patients who achieved CR or better (34.6% and18.6%, respectively). Taken collectively, these findings emphasize the importance of sustained MRD negativity, Voorhees concludes.